A Cambridge MedTech behind a ‘Breath Biopsy’ platform which aims to diagnose disease has raised £22m in Series E funding. Owlstone Medical is developing breath tests and point-of-care devices for lung cancer, liver disease and digestive disease. These include in-human clinical trials currently underway for a screening test for the early-stage detection of lung cancer, … Continue reading Owlstone raises £22m for Breath Biopsy diagnostic tests